SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects
Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the …
SE Inzucchi, RM Bergenstal, JB Buse… - Diabetes …, 2015 - Am Diabetes Assoc
In 2012, the American Diabetes Association (ADA) and the European Association for the
Study of Diabetes (EASD) published a position statement on the management of …
Study of Diabetes (EASD) published a position statement on the management of …
Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis
F Zaccardi, DR Webb, ZZ Htike… - Diabetes, Obesity …, 2016 - Wiley Online Library
Aim To assess the comparative efficacy and safety of sodium‐glucose co‐transporter‐2
(SGLT2) inhibitors in adults with type 2 diabetes. Methods We electronically searched …
(SGLT2) inhibitors in adults with type 2 diabetes. Methods We electronically searched …
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the …
SE Inzucchi, RM Bergenstal, JB Buse, M Diamant… - Diabetologia, 2015 - Springer
Diabetologia (2015) 58: 429–442 DOI 10.1007/s00125-014-3460-0 management of
hyperglycaemia in patients with type 2 diabetes [1, 2]. This was needed because of an …
hyperglycaemia in patients with type 2 diabetes [1, 2]. This was needed because of an …
Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus
AJ Scheen - Drugs, 2015 - Springer
Inhibitors of sodium–glucose co-transporter type 2 (SGLT2) are proposed as a novel
approach for the management of type 2 diabetes mellitus (T2DM). Several compounds are …
approach for the management of type 2 diabetes mellitus (T2DM). Several compounds are …
Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis
Objective Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for
the treatment of diabetes. We aimed at describing the maximal benefits and risks associated …
the treatment of diabetes. We aimed at describing the maximal benefits and risks associated …
The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet
JH Han, TJ Oh, G Lee, HJ Maeng, DH Lee, KM Kim… - Diabetologia, 2017 - Springer
Aims/hypothesis A recent large clinical study has shown that empagliflozin has a lower rate
of cardiovascular and all-cause mortality when compared with placebo in patients with type …
of cardiovascular and all-cause mortality when compared with placebo in patients with type …
Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes
S Sugiyama, H Jinnouchi, N Kurinami… - … of atherosclerosis and …, 2018 - jstage.jst.go.jp
Aim: Sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy has been demonstrated to
improve glycemic control and reduce body weight and fat mass in type 2 diabetes mellitus …
improve glycemic control and reduce body weight and fat mass in type 2 diabetes mellitus …
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
P Fioretto, A Giaccari, G Sesti - Cardiovascular diabetology, 2015 - Springer
Although antidiabetic agents have been developed to target one or more of the core defects
of type 2 diabetes mellitus (T2DM), many patients do not achieve glycemic goals. Inhibition …
of type 2 diabetes mellitus (T2DM), many patients do not achieve glycemic goals. Inhibition …
Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
R Johnston, OA Uthman, E Cummins… - Health Technology …, 2017 - wrap.warwick.ac.uk
Background Most people with type 2 diabetes are overweight, so initial treatment is aimed at
reducing weight and increasing physical activity. Even modest weight loss can improve …
reducing weight and increasing physical activity. Even modest weight loss can improve …